

Oral Anticoagulants in Atrial Fibrillation

Reference List

1. Gauthier K, Richter T, Bai A, Moulton K, Spry C, Boucher M. Antithrombotic agents for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Canadian Agency for Drugs and Technologies in Health Therapeutic Review. 2013 Mar; Available from: <http://www.ncbi.nlm.nih.gov/books/NBK168988/>
2. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;(3):CD001927.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857–67.
4. Institute for Safe Medication Practices Quarter Watch. Anticoagulants leading drug safety problem reported directly to FDA [Internet]. [cited 2014 Mar 18]. Available from: <http://www.ismp.org/QuarterWatch/default.aspx>
5. Wells G, Coyle D, Cameron C, Steiner S, Coyle K, Kelly S, et al. Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Canadian Collaborative for Drug Safety, Effectiveness and Network Meta-Analysis Therapeutic Review. 2012 Apr; Available from: <http://www.ncbi.nlm.nih.gov/books/NBK169797/>
6. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. CHEST. 2012 Feb;141(2 Suppl):e531S–75S.
7. Murad MH, Montori VM. Synthesizing evidence: shifting the focus from individual studies to the body of evidence. JAMA. 2013 Jun;309(21):2217–8.
8. Canadian Agency for Drugs and Technologies in Health. Recommendations for antithrombotic agents for the prevention of stroke and systemic embolism in patients with atrial fibrillation. 2013 Mar; Available from: http://www.cadth.ca/media/pdf/TR0003_AntithromboticAgents-AF_RecsReport-e.pdf
9. Australian Department of Health and Ageing. Review of anticoagulation therapies in atrial fibrillation. 2012 Oct; Available from: <http://www.pbs.gov.au/info/publication/factsheets/shared/anticoagulation-review>

10. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. *Can J Cardiol*. 2012 Apr;28(2):125–36.
11. Adam SS, McDuffie JR, Ortel TL, Williams JW Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. *Ann Intern Med*. 2012 Dec;157(11):796–807.
12. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. *Circ Cardiovasc Qual Outcomes*. 2012 Jul;5(4):480–6.
13. Mini-Sentinel Distributed Database. A protocol for assessment of dabigatran and selected safety outcomes. 2013 Dec [Internet]. [cited 2014 Mar 7]. Available from: http://mini-sentinel.org/assessments/medical_events/details.aspx?ID=219
14. Mini-Sentinel Distributed Database. PROMPT: rivaroxaban surveillance plan. 2014 Jan. [Internet]. [cited 2014 Mar 7]. Available from: http://mini-sentinel.org/assessments/medical_events/details.aspx?ID=230
15. Gonzalez-Quesada CJ, Giugliano RP. Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice. *Am J Cardiovasc Drugs*. 2014 Feb;14(2):111–27.
16. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. *Lancet*. 2010 Sep;376(9745):975–83.
17. Van Spall HGC, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. *Circulation*. 2012 Nov;126(19):2309–16.
18. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. *J Am Heart Assoc*. 2013 Feb;2(1):e000067.
19. Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. *Circulation*. 2013 Jun 4;127(22):2166–76.
20. Mulla SM, Scott IA, Jackevicius CA, You JJ, Guyatt GH. How to use a noninferiority trial: users' guides to the medical literature. *JAMA*. 2012 Dec;308(24):2605–11.
21. US Food and Drug Administration. Dabigatran Medical Review. NDA 022512 [Internet]. 2010 [cited 2014 Mar 6]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000MedR.pdf
22. US Food and Drug Administration. Cardiovascular and Renal Drugs Advisory Committee. September 20, 2010. [Internet]. [cited 2014 Mar 6]. Available from: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM233739.pdf>
23. Therapeutics Initiative. Dabigatran for atrial fibrillation: Why we can not rely on RE-LY. 2012 Aug;80:1–2.

24. US Food and Drug Administration. Xarelto (rivaroxaban) FDA draft briefing document for the Cardiovascular and Renal Drug Advisory Committee (CRDAC). September 2011 [Internet]. [cited 2014 Mar 6]. Available from:
<http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270796.pdf>
25. US Food and Drug Administration. Cardiovascular and Renal Drugs Advisory Committee. Transcript September 8, 2011 [Internet]. [cited 2014 Mar 6]. Available from:
<http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM277588.pdf>
26. US Food and Drug Administration. Apixaban Medical Review. NDA 202155 [Internet]. 2012 [cited 2014 Mar 6]. Available from:
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000MedR.pdf
27. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. CHEST. 2012 Feb;141(2 Suppl):e152S–84S.
28. Canadian Agency for Drugs and Technologies in Health. Anticoagulation monitoring and reversal strategies for dabigatran, rivaroxaban, and apixaban: A review of clinical effectiveness. 2012 Apr; Available from: http://www.cadth.ca/media/pdf/TR0002_New_Oral_Anticoagulants.pdf
29. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012 Nov;33(21):2719–47.
30. Adam SS, McDuffie JR, Ortel TL, Nagi A, Williams JW. Comparative effectiveness of warfarin and newer oral anticoagulants for the long-term prevention and treatment of arterial and venous thromboembolism. VA-ESP Project #09-010. Washington (DC): Department of Veterans Affairs; 2012. Available from:
<http://www.ncbi.nlm.nih.gov/books/NBK97541/>
31. Lopes RD, Crowley MJ, Shah BR, Melloni C, Wood KA, Chatterjee R, et al. Stroke prevention in atrial fibrillation. Comparative Effectiveness Review No. 123. (Prepared by the Duke Evidence-based Practice Center under contract no. 290-2007-10066-I) AHRQ Publication No. 13-EHC113-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2013. Available from:
<http://www.effectivehealthcare.ahrq.gov/ehc/products/352/1668/stroke-atrial-fibrillation-report-130821.pdf>
32. Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013 Jul;29(7 Suppl):S24–33.
33. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. CHEST. 2012 Feb;141(2 Suppl):e326S–50S.
34. Beasley BN, Unger EF, Temple R. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011 May 12;364(19):1788–90.
35. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012 Mar 1;366(9):864–6.

36. Stöllberger C, Finsterer J. Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation. *Drugs Aging*. 2013 Dec;30(12):949–58.
37. Kim D, Barna R, Bridgeman MB, Brunetti L. Novel oral anticoagulants for stroke prevention in the geriatric population. *Am J Cardiovasc Drugs*. 2014 Feb;14(1):15–29.
38. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). *J Am Coll Cardiol*. 2014 Feb 4;63(4):321–8.
39. Hart RG, Eikelboom JW, Brimble KS, McMurry MS, Ingram AJ. Stroke prevention in atrial fibrillation patients with chronic kidney disease. *Can J Cardiol*. 2013 Jul;29(7 Suppl):S71–8.
40. Boehringer Ingelheim. Dear health care professional letters - Updated new recommendations for Pradox (dabigatran etexilate) regarding renal function assessment, and use in patients with severe valvular disease or prosthetic heart valves [Internet]. 2012 [cited 2014 Mar 19]. Available from: http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/120316-dhcpl.pdf
41. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. *Eur Heart J*. 2013 Jul;34(27):2094–106.
42. Stöllberger C, Finsterer J. Reservations against new oral anticoagulants after stroke and cerebral bleeding. *J Neurol Sci*. 2013 Jul;330(1-2):16–7.
43. Deitelzweig SB. Transitions of care in anticoagulation management for patients with atrial fibrillation. *Hosp Pract*. 2012 Oct;40(4):20–7.
44. Boehringer Ingelheim. Dear health care professional letters- Pradaxa/Pradox (dabigatran etexilate): new contraindication in patients with prosthetic heart valves requiring anticoagulation treatment due to their valvular status [Internet]. [cited 2014 Mar 20]. Available from: http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/121221-hpc-final-dated-Dec-21.pdf
45. Whitlock RP, Sun JC, Frenes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012 Feb;141(2 Suppl):e576S–600S.
46. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. *Circulation*. 2014 Mar;127.
47. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009 Sep 17;361(12):1139–51.
48. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011 Sep 8;365(10):883–91.
49. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011 Sep 15;365(11):981–92.

50. Mahtani KR, Heneghan CJ, Nunan D, Bankhead C, Keeling D, Ward AM, et al. Optimal loading dose of warfarin for the initiation of oral anticoagulation. *Cochrane Database Syst Rev*. 2012;12:CD008685.
51. Guidelines and Protocols Advisory Committee. Warfarin Therapy Management. Effective date: October 1, 2010 [Internet]. 2010 [cited 2014 Mar 19]. Available from: http://www.bcguidelines.ca/pdf/warfarin_management.pdf
52. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012 Feb;141(2 Suppl):e44S–88S.
53. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. *Chest*. 2005 Jun;127(6):2049–56.
54. Canadian Agency for Drugs and Technologies in Health. Preventing stroke in patients with atrial fibrillation: using the evidence [Internet]. 2013 [cited 2014 Mar 19]. Available from: http://www.cadth.ca/media/pdf/CADTH-NOAC-brochure.pdf?utm_source=new-at-cadth-oct2013&utm_medium=webmail&utm_content=noac-brochure&utm_campaign=nac-oct2013
55. Canadian Agency for Drugs and Technologies in Health. Optimal warfarin management for the prevention of thromboembolic events in patients with atrial fibrillation: a systematic review of the clinical evidence. *CADTH Technol Overv*. 2012;2(3):e2304.
56. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. *Arch Intern Med*. 2005 May 23;165(10):1095–106.
57. Dumont Z, Kosar L. Warfarin tips and dosing nomograms [Internet]. 2013 [cited 2014 Mar 4]. Available from: http://www.cfp.ca/content/suppl/2013/08/13/59.8.856.DC1/Warfarin_Tips.pdf
58. Lexi-Comp, Inc. Lexi-Drugs. Lexi-Drugs, Inc.;version 2.0.1(165). Accessed March 4, 2014.
59. University of Washington Medicine Anticoagulation Services. Warfarin drug interactions [Internet]. [cited 2014 Mar 20]. Available from: <http://depts.washington.edu/anticoag/home/content/warfarin-drug-interactions>
60. Canadian Pharmacists Association. Coumadin [product monograph]. e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2014 [cited 2014 Mar 20]. Available from: <http://www.e-cps.ca>
61. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. *Circulation*. 2013 Feb 5;127(5):634–40.
62. Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. *Eur Heart J*. 2014 Jan;35(4):224–32.
63. Canadian Pharmacists Association. Pradaxa [product monograph]. e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2014 [cited 2014 Mar 20]. Available from: <http://www.e-cps.ca>
64. Canadian Pharmacists Association. Xarelto [product monograph]. e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2014 [cited 2014 Mar 20]. Available from: <http://www.e-cps.ca>
65. Canadian Pharmacists Association. Eliquis [product monograph]. e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2014 [cited 2014 Mar 20]. Available from: <http://www.e-cps.ca>
66. University of Washington Medicine Anticoagulation Services. Anticoagulation services [Internet]. [cited 2014 Mar 19]. Available from: <http://depts.washington.edu/anticoag/home/>

67. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. *Blood*. 2012 Mar;119(13):3016–23.
68. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. *N Engl J Med*. 2013 Sep 26;369(13):1206–14.
69. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. *Am Heart J*. 2009 May;157(5):805–810, 810.e1–2.
70. Boehringer Ingelheim. Advisory Committee Briefing Document - dabigatran etexilate (DE) [Internet]. 2010 Aug [cited 2014 Mar 27]. Available from: <http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf>
71. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. *Am Heart J*. 2010 Mar;159(3):340–7.e1.
72. Johnson & Johnson Pharmaceutical Research & Development. Advisory committee briefing document - rivaroxaban [Internet]. 2011 Aug [cited 2014 Mar 20]. Available from: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270797.pdf>
73. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET-AF Trial [Internet]. [cited 2014 Apr 2]. Available from: http://conference-cast.com/aha/media/AHA2012ISC_7/A22/3562/3562.pdf
74. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, et al. Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. *Am Heart J*. 2010 Mar;159(3):331–9.
75. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. *N Engl J Med*. 2010 Nov 4;363(19):1875–6.
76. Nessel CC, Mahaffey KW, Piccini JP, Pan G, Patel MR, Becker RC, et al. Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKET AF trial. *CHEST*. 2012;142(4 Meeting Abstracts):84A.
77. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN. Rates of hemorrhage during warfarin therapy for atrial fibrillation. *CMAJ*. 2013 Feb;185(2):e121–7.
78. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. *Arch Intern Med*. 2012 Mar 12;172(5):397–402.
79. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. *Circulation*. 2011 May;123(21):2363–72.